HIV-1 tuberculosis-associated immune reconstitution inflammatory syndrome

Seminars in Immunopathology

Volumn 38, Issue 2, 2016, Pages 185-198

  Lai, Rachel P J ^a   Meintjes, Graeme ^b,c,d   Wilkinson, Robert J ^a,b,c,d  

^a THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Drug therapy complications; HIV 1 infection; Immune reconstitution inflammatory syndrome; Tuberculosis

Indexed keywords

ADALIMUMAB; ANTIRETROVIRUS AGENT; COLECALCIFEROL; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE B; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; KI 67 ANTIGEN; MATRILYSIN; MONTELUKAST; MYCOBACTERIUM ANTIGEN; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; PLACEBO; PREDNISONE; PROGRAMMED DEATH 1 RECEPTOR; THALIDOMIDE; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL FEATURE; DISEASE MODEL; DRUG EFFICACY; DRUG SAFETY; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOPATHOGENESIS; INCIDENCE; INNATE IMMUNITY; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; MIXED INFECTION; MONOCYTE; MYCOBACTERIUM TUBERCULOSIS; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; RISK FACTOR; TUBERCULOSIS; TUBERCULOSIS ASSOCIATED IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; ANIMAL; COMPLICATION; CYTOLOGY; DISEASE MANAGEMENT; DRUG EFFECTS; HIV INFECTIONS; HOST PATHOGEN INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE SYSTEM; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; SIGNAL TRANSDUCTION; VIROLOGY;

ANIMALS; COINFECTION; DISEASE MANAGEMENT; DISEASE MODELS, ANIMAL; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE SYSTEM; MYCOBACTERIUM TUBERCULOSIS; RISK FACTORS; SIGNAL TRANSDUCTION; TUBERCULOSIS;

EID: 84959490878     PISSN: 18632297     EISSN: 18632300     Source Type: Journal    
DOI: 10.1007/s00281-015-0532-2     Document Type: Review

References (147)

1. WHO (2014) Global Health Observatory (GHO) data. http://www.who.int/gho/hiv/en/
2. WHO (2014) World Health Organization: Global Tuberculosis Report 2014. http://www.who.int/tb/publications/global_report/en/
3. Kony SJ, Hane AA, Larouze B, Samb A, Cissoko S, Sow PS et al (2000) Tuberculosis-associated severe CD4+ T-lymphocytopenia in HIV-seronegative patients from Dakar. SIDAK Research Group. J Infect 41:167–171
4. Pilheu JA, De Salvo MC, Gonzalez J, Rey D, Elias MC, Ruppi MC (1997) CD4+ T-lymphocytopenia in severe pulmonary tuberculosis without evidence of human immunodeficiency virus infection. Int J Tuberc Lung Dis 1:422–426
5. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J (1995) Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 151:129–135
6. WHO (2015) A guide to monitoring and evaluation for collaborative TB/HIV activities. http://apps.who.int/iris/bitstream/10665/150627/1/9789241508278_eng.pdf?ua=1
7. Diedrich CR, Flynn JL (2011) HIV-1/Mycobacterium tuberculosis coinfection immunology: how does HIV-1 exacerbate tuberculosis? Infect Immun 79:1407–1417
8. Hoshino Y, Hoshino S, Gold JA, Raju B, Prabhakar S, Pine R et al (2007) Mechanisms of polymorphonuclear neutrophil-mediated induction of HIV-1 replication in macrophages during pulmonary tuberculosis. J Infect Dis 195:1303–1310
9. Hoshino Y, Nakata K, Hoshino S, Honda Y, Tse DB, Shioda T et al (2002) Maximal HIV-1 replication in alveolar macrophages during tuberculosis requires both lymphocyte contact and cytokines. J Exp Med 195:495–505
10. Lawn SD, Pisell TL, Hirsch CS, Wu M, Butera ST, Toossi Z (2001) Anatomically compartmentalized human immunodeficiency virus replication in HLA-DR+ cells and CD14+ macrophages at the site of pleural tuberculosis coinfection. J Infect Dis 184:1127–1133
11. Nakata K, Rom WN, Honda Y, Condos R, Kanegasaki S, Cao Y et al (1997) Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in the lung. Am J Respir Crit Care Med 155:996–1003
12. Kumawat K, Pathak SK, Spetz AL, Kundu M, Basu J (2010) Exogenous Nef is an inhibitor of Mycobacterium tuberculosis-induced tumor necrosis factor-alpha production and macrophage apoptosis. J Biol Chem 285:12629–12637
13. Patel NR, Zhu J, Tachado SD, Zhang J, Wan Z, Saukkonen J et al (2007) HIV impairs TNF-alpha mediated macrophage apoptotic response to Mycobacterium tuberculosis. J Immunol 179:6973–6980
14. Geldmacher C, Schuetz A, Ngwenyama N, Casazza JP, Sanga E, Saathoff E et al (2008) Early depletion of Mycobacterium tuberculosis-specific T helper 1 cell responses after HIV-1 infection. J Infect Dis 198:1590–1598
15. Hertoghe T, Wajja A, Ntambi L, Okwera A, Aziz MA, Hirsch C et al (2000) T cell activation, apoptosis and cytokine dysregulation in the (co)pathogenesis of HIV and pulmonary tuberculosis (TB). Clin Exp Immunol 122:350–357
16. Kalsdorf B, Scriba TJ, Wood K, Day CL, Dheda K, Dawson R et al (2009) HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria. Am J Respir Crit Care Med 180:1262–1270
17. Mendonca M, Tanji MM, Silva LC, Silveira GG, Oliveira SC, Duarte AJ et al (2007) Deficient in vitro anti-mycobacterial immunity despite successful long-term highly active antiretroviral therapy in HIV-infected patients with past history of tuberculosis infection or disease. Clin Immunol 125:60–66
18. Zhang M, Gong J, Iyer DV, Jones BE, Modlin RL, Barnes PF (1994) T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection. J Clin Invest 94:2435–2442
19. Suthar AB, Lawn SD, del Amo J, Getahun H, Dye C, Sculier D et al (2012) Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med 9, e1001270
20. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R et al (1997) Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277:112–116
21. Wilkinson KA, Seldon R, Meintjes G, Rangaka MX, Hanekom WA, Maartens G et al (2009) Dissection of regenerating T-Cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis. Am J Respir Crit Care Med 180:674–683
22. Sutherland JS, Young JM, Peterson KL, Sanneh B, Whittle HC, Rowland-Jones SL et al (2010) Polyfunctional CD4(+) and CD8(+) T cell responses to tuberculosis antigens in HIV-1-infected patients before and after anti-retroviral treatment. J Immunol 184:6537–6544
23. French MA, Mallal SA, Dawkins RL (1992) Zidovudine-induced restoration of cell-mediated immunity to mycobacteria in immunodeficient HIV-infected patients. Aids 6:1293–1297
24. Lawn SD, Bekker LG, Miller RF (2005) Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 5:361–373
25. Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M et al (2010) Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 10:251–261
26. Namale PE, Abdullahi LH, Fine S, Kamkuemah M, Wilkinson RJ, Meintjes G (2015) Paradoxical TB-IRIS in HIV-infected adults: a systematic review and meta-analysis. Future Microbiol 10:1077–1099
27. Marais S, Meintjes G, Pepper DJ, Dodd LE, Schutz C, Ismail Z et al (2013) Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome. Clin Infect Dis 56:450–460
28. Asselman V, Thienemann F, Pepper DJ, Boulle A, Wilkinson RJ, Meintjes G et al (2010) Central nervous system disorders after starting antiretroviral therapy in South Africa. Aids 24:2871–2876
29. Pepper DJ, Marais S, Maartens G, Rebe K, Morroni C, Rangaka MX et al (2009) Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series. Clin Infect Dis 48:e96–e107
30. Colebunders R, John L, Huyst V, Kambugu A, Scano F, Lynen L (2006) Tuberculosis immune reconstitution inflammatory syndrome in countries with limited resources. Int J Tuberc Lung Dis 10:946–953
31. French MA, Price P, Stone SF (2004) Immune restoration disease after antiretroviral therapy. Aids 18:1615–1627
32. Robertson J, Meier M, Wall J, Ying J, Fichtenbaum CJ (2006) Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis 42:1639–1646
33. Shelburne SA 3rd, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DW et al (2002) Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine 81:213–227
34. Shelburne SA, Montes M, Hamill RJ (2006) Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chem 57:167–170
35. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W et al (2008) Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 8:516–523
36. Eshun-Wilson I, Havers F, Nachega JB, Prozesky HW, Taljaard JJ, Zeier MD et al (2010) Evaluation of paradoxical TB-associated IRIS with the use of standardized case definitions for resource-limited settings. J Int Assoc Phys AIDS Care 9:104–108
37. Haddow LJ, Moosa MY, Easterbrook PJ (2010) Validation of a published case definition for tuberculosis-associated immune reconstitution inflammatory syndrome. Aids 24:103–108
38. Haddow LJ, Easterbrook PJ, Mosam A, Khanyile NG, Parboosing R, Moodley P et al (2009) Defining immune reconstitution inflammatory syndrome: evaluation of expert opinion versus 2 case definitions in a South African cohort. Clin Infect Dis 49:1424–1432
39. Sharma SK, Dhooria S, Barwad P, Kadhiravan T, Ranjan S, Miglani S et al (2010) A study of TB-associated immune reconstitution inflammatory syndrome using the consensus case-definition. Indian J Med Res 131:804–808
40. French MA, Lenzo N, John M, Mallal SA, McKinnon EJ, James IR et al (2000) Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 1:107–115
41. Jevtovic DJ, Salemovic D, Ranin J, Pesic I, Zerjav S, Djurkovic-Djakovic O (2005) The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy. HIV Med 6:140–143
42. Lawn SD, Myer L, Bekker LG, Wood R (2007) Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. Aids 21:335–341
43. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ (2006) Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 42:418–427
44. Bourgarit A, Carcelain G, Martinez V, Lascoux C, Delcey V, Gicquel B et al (2006) Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. Aids 20:F1–F7
45. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL et al (2011) Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 365:1492–1501
46. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E et al (2011) Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 365:1471–1481
47. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS et al (2011) Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 365:1482–1491
48. Burman W, Weis S, Vernon A, Khan A, Benator D, Jones B et al (2007) Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis. Int J Tuberc Lung Dis 11:1282–1289
49. Manosuthi W, Kiertiburanakul S, Phoorisri T, Sungkanuparph S (2006) Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J Infect 53:357–363
50. Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK, Cdc et al (2004) Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Recommend Rep 53:1–112
51. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN et al (2003) American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 167:603–662
52. Breen RA, Smith CJ, Bettinson H, Dart S, Bannister B, Johnson MA et al (2004) Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax 59:704–707
53. Meintjes G, Wilkinson RJ, Morroni C, Pepper DJ, Rebe K, Rangaka MX et al (2010) Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. Aids 24:2381–2390
54. Meintjes G, Skolimowska KH, Wilkinson KA, Matthews K, Tadokera R, Conesa-Botella A et al (2012) Corticosteroid-modulated immune activation in the tuberculosis immune reconstitution inflammatory syndrome. Am J Respir Crit Care Med 186:369–377
55. Elliott AM, Luzze H, Quigley MA, Nakiyingi JS, Kyaligonza S, Namujju PB et al (2004) A randomized, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1-associated pleural tuberculosis. J Infect Dis 190:869–878
56. Volkow PF, Cornejo P, Zinser JW, Ormsby CE, Reyes-Teran G (2008) Life-threatening exacerbation of Kaposi's sarcoma after prednisone treatment for immune reconstitution inflammatory syndrome. Aids 22:663–665
57. Meintjes G, Rangaka MX, Maartens G, Rebe K, Morroni C, Pepper DJ et al (2009) Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. Clin Infect Dis 48:667–676
58. AIDSInfo (2009) Guidelines for prevention and treatment of opportunistic Infections in HIV-infected adults and adolescents
59. Roberts MT, Mendelson M, Meyer P, Carmichael A, Lever AM (2003) The use of thalidomide in the treatment of intracranial tuberculomas in adults: two case reports. J Infect 47:251–255
60. Schoeman JF, Fieggen G, Seller N, Mendelson M, Hartzenberg B (2006) Intractable intracranial tuberculous infection responsive to thalidomide: report of four cases. J Child Neurol 21:301–308
61. Brunel AS, Reynes J, Tuaillon E, Rubbo PA, Lortholary O, Montes B et al (2012) Thalidomide for steroid-dependent immune reconstitution inflammatory syndromes during AIDS. Aids 26:2110–2112
62. Fernandes GC, Vieira MA, Lourenco MC, Gadelha AJ, Coura LC, Rolla VC (2002) Inflammatory paradoxical reaction occurring in tuberculosis patients treated with HAART and rifampicin. Rev Inst Med Trop Sao Paulo 44:113–114
63. Lortholary O, Fontanet A, Memain N, Martin A, Sitbon K, Dromer F et al (2005) Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. Aids 19:1043–1049
64. van Toorn R, Rabie H, Dramowski A, Schoeman JF (2012) Neurological manifestations of TB-IRIS: a report of 4 children. Eur J Paediatr Neurol 16:676–682
65. Mayer-Barber KD, Andrade BB, Oland SD, Amaral EP, Barber DL, Gonzales J et al (2014) Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 511:99–103
66. Hardwick C, White D, Morris E, Monteiro EF, Breen RA, Lipman M (2006) Montelukast in the treatment of HIV associated immune reconstitution disease. Sex Transm Infect 82:513–514
67. Lipman MC, Carding SK (2007) Successful drug treatment of immune reconstitution disease with the leukotriene receptor antagonist, montelukast: a clue to pathogenesis? Aids 21:383–384
68. Bell HC, Heath CH, French MA (2005) Pulmonary Mycobacterium celatum immune restoration disease: immunopathology and response to corticosteroid therapy. Aids 19:2047–2049
69. Boelaert JR, Goddeeris KH, Vanopdenbosch LJ, Casselman JW (2004) Relapsing meningitis caused by persistent cryptococcal antigens and immune reconstitution after the initiation of highly active antiretroviral therapy. Aids 18:1223–1224
70. John M, French MA (1998) Exacerbation of the inflammatory response to Mycobacterium tuberculosis after antiretroviral therapy. Med J Aust 169:473–474
71. Wallis RS, Johnson JL, Okwera A, Nsubuga P, Whalen CC, Mugerwa RD et al (1998) Pentoxifylline in human immunodeficiency virus- positive tuberculosis: safety at 4 years. J Infect Dis 178:1861
72. Wallis RS, van Vuuren C, Potgieter S (2009) Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis 48:1429–1432
73. Lee HS, Lee Y, Lee SO, Choi SH, Kim YS, Woo JH et al (2012) Adalimumab treatment may replace or enhance the activity of steroids in steroid-refractory tuberculous meningitis. J Infect Chemother 18:555–557
74. Blackmore TK, Manning L, Taylor WJ, Wallis RS (2008) Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. Clin Infect Dis 47:e83–e85
75. Sitapati AM, Kao CL, Cachay ER, Masoumi H, Wallis RS, Mathews WC (2010) Treatment of HIV-related inflammatory cerebral cryptococcoma with adalimumab. Clin Infect Dis 50:e7–e10
76. Ravimohan S, Tamuhla N, Steenhoff AP, Letlhogile R, Nfanyana K, Bellamy SL et al (2015) Immunological profiling of tuberculosis-associated immune reconstitution inflammatory syndrome and non-immune reconstitution inflammatory syndrome death in HIV-infected adults with pulmonary tuberculosis starting antiretroviral therapy: a prospective observational cohort study. Lancet Infect Dis 15:429–438
77. Tadokera R, Meintjes G, Skolimowska KH, Wilkinson KA, Matthews K, Seldon R et al (2011) Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome. Eur Respir J 37:1248–1259
78. Breton G, Duval X, Estellat C, Poaletti X, Bonnet D, Mvondo Mvondo D et al (2004) Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis 39:1709–1712
79. Meintjes G, Wilkinson KA, Rangaka MX, Skolimowska K, van Veen K, Abrahams M et al (2008) Type 1 helper T cells and FoxP3-positive T cells in HIV-tuberculosis-associated immune reconstitution inflammatory syndrome. Am J Respir Crit Care Med 178:1083–1089
80. Tieu HV, Ananworanich J, Avihingsanon A, Apateerapong W, Sirivichayakul S, Siangphoe U et al (2009) Immunologic markers as predictors of tuberculosis-associated immune reconstitution inflammatory syndrome in HIV and tuberculosis coinfected persons in Thailand. AIDS Res Hum Retrovir 25:1083–1089
81. Elliott JH, Vohith K, Saramony S, Savuth C, Dara C, Sarim C et al (2009) Immunopathogenesis and diagnosis of tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome during early antiretroviral therapy. J Infect Dis 200:1736–1745
82. Antonelli LR, Mahnke Y, Hodge JN, Porter BO, Barber DL, DerSimonian R et al (2010) Elevated frequencies of highly activated CD4+ T cells in HIV+ patients developing immune reconstitution inflammatory syndrome. Blood 116:3818–3827
83. Chakrabarti LA, Boucherie C, Bugault F, Cumont MC, Roussillon C, Breton G et al (2014) Biomarkers of CD4+ T-cell activation as risk factors for tuberculosis-associated immune reconstitution inflammatory syndrome. Aids 28:1593–1602
84. Mahnke YD, Greenwald JH, DerSimonian R, Roby G, Antonelli LR, Sher A et al (2012) Selective expansion of polyfunctional pathogen-specific CD4(+) T cells in HIV-1-infected patients with immune reconstitution inflammatory syndrome. Blood 119:3105–3112
85. Sakaguchi S (2005) Naturally arising Foxp3-expressing CD25+ CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6:345–352
86. Scott-Browne JP, Shafiani S, Tucker-Heard G, Ishida-Tsubota K, Fontenot JD, Rudensky AY et al (2007) Expansion and function of Foxp3-expressing T regulatory cells during tuberculosis. J Exp Med 204:2159–2169
87. Guyot-Revol V, Innes JA, Hackforth S, Hinks T, Lalvani A (2006) Regulatory T cells are expanded in blood and disease sites in patients with tuberculosis. Am J Respir Crit Care Med 173:803–810
88. Seddiki N, Sasson SC, Santner-Nanan B, Munier M, van Bockel D, Ip S et al (2009) Proliferation of weakly suppressive regulatory CD4+ T cells is associated with over-active CD4+ T-cell responses in HIV-positive patients with mycobacterial immune restoration disease. Eur J Immunol 39:391–403
89. Tan DB, Yong YK, Tan HY, Kamarulzaman A, Tan LH, Lim A et al (2008) Immunological profiles of immune restoration disease presenting as mycobacterial lymphadenitis and cryptococcal meningitis. HIV Med 9:307–316
90. Matsuda JL, Mallevaey T, Scott-Browne J, Gapin L (2008) CD1d-restricted iNKT cells, the 'Swiss-Army knife' of the immune system. Curr Opin Immunol 20:358–368
91. Rojas RE, Chervenak KA, Thomas J, Morrow J, Nshuti L, Zalwango S et al (2005) Vdelta2+ gammadelta T cell function in Mycobacterium tuberculosis- and HIV-1-positive patients in the United States and Uganda: application of a whole-blood assay. J Infect Dis 192:1806–1814
92. Shen Y, Zhou D, Qiu L, Lai X, Simon M, Shen L et al (2002) Adaptive immune response of Vgamma2Vdelta2+ T cells during mycobacterial infections. Science 295:2255–2258
93. Kabelitz D, Bender A, Schondelmaier S, Schoel B, Kaufmann SH (1990) A large fraction of human peripheral blood gamma/delta + T cells is activated by Mycobacterium tuberculosis but not by its 65-kD heat shock protein. J Exp Med 171:667–679
94. Gioia C, Agrati C, Casetti R, Cairo C, Borsellino G, Battistini L et al (2002) Lack of CD27-CD45RA-V gamma 9V delta 2+ T cell effectors in immunocompromised hosts and during active pulmonary tuberculosis. J Immunol 168:1484–1489
95. Bourgarit A, Carcelain G, Samri A, Parizot C, Lafaurie M, Abgrall S et al (2009) Tuberculosis-associated immune restoration syndrome in HIV-1-infected patients involves tuberculin-specific CD4 Th1 cells and KIR-negative gammadelta T cells. J Immunol 183:3915–3923
96. Wilkinson KA, Walker NF, Meintjes G, Deffur A, Nicol MP, Skolimowska KH et al (2015) Cytotoxic mediators in paradoxical HIV-tuberculosis immune reconstitution inflammatory syndrome. J Immunol 194:1748–1754
97. Espinosa E, Ormsby CE, Vega-Barrientos RS, Ruiz-Cruz M, Moreno-Coutino G, Pena-Jimenez A et al (2010) Risk factors for immune reconstitution inflammatory syndrome under combination antiretroviral therapy can be aetiology-specific. Int J STD AIDS 21:573–579
98. Lim A, D'Orsogna L, Price P, French MA (2008) Imbalanced effector and regulatory cytokine responses may underlie mycobacterial immune restoration disease. AIDS Res Ther 5:9
99. Skolimowska KH, Rangaka MX, Meintjes G, Pepper DJ, Seldon R, Matthews K et al (2012) Altered ratio of IFN-gamma/IL-10 in patients with drug resistant Mycobacterium tuberculosis and HIV-Tuberculosis Immune Reconstitution Inflammatory Syndrome. PLoS One 7, e46481
100. Grant PM, Komarow L, Lederman MM, Pahwa S, Zolopa AR, Andersen J et al (2012) Elevated interleukin 8 and T-helper 1 and T-helper 17 cytokine levels prior to antiretroviral therapy in participants who developed immune reconstitution inflammatory syndrome during ACTG A5164. J Infect Dis 206:1715–1723
101. Morlese JF, Orkin CM, Abbas R, Burton C, Qazi NA, Nelson MR et al (2003) Plasma IL-6 as a marker of mycobacterial immune restoration disease in HIV-1 infection. Aids 17:1411–1413
102. Worsley CM, Suchard MS, Stevens WS, Van Rie A, Murdoch DM (2010) Multi-analyte profiling of ten cytokines in South African HIV-infected patients with Immune Reconstitution Inflammatory Syndrome (IRIS). AIDS Res Ther 7:36
103. Narendran G, Andrade BB, Porter BO, Chandrasekhar C, Venkatesan P, Menon PA et al (2013) Paradoxical tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS) in HIV patients with culture confirmed pulmonary tuberculosis in India and the potential role of IL-6 in prediction. PLoS One 8, e63541
104. Barber DL, Andrade BB, McBerry C, Sereti I, Sher A (2014) Role of IL-6 in Mycobacterium avium-associated immune reconstitution inflammatory syndrome. J Immunol 192:676–682
105. Tadokera R, Wilkinson KA, Meintjes GA, Skolimowska KH, Matthews K, Seldon R et al (2013) Role of the interleukin 10 family of cytokines in patients with immune reconstitution inflammatory syndrome associated with HIV infection and tuberculosis. J Infect Dis 207:1148–1156
106. Khader SA, Gaffen SL, Kolls JK (2009) Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. Mucosal Immunol 2:403–411
107. Oliver BG, Elliott JH, Price P, Phillips M, Saphonn V, Vun MC et al (2010) Mediators of innate and adaptive immune responses differentially affect immune restoration disease associated with Mycobacterium tuberculosis in HIV patients beginning antiretroviral therapy. J Infect Dis 202:1728–1737
108. Tan HY, Yong YK, Andrade BB, Shankar EM, Ponnampalavanar S, Omar SF et al (2015) Plasma interleukin-18 levels are a biomarker of innate immune responses that predict and characterize tuberculosis-associated immune reconstitution inflammatory syndrome. Aids 29:421–431
109. Conesa-Botella A, Meintjes G, Coussens AK, van der Plas H, Goliath R, Schutz C et al (2012) Corticosteroid therapy, vitamin D status, and inflammatory cytokine profile in the HIV-tuberculosis immune reconstitution inflammatory syndrome. Clin Infect Dis 55:1004–1011
110. Marais S, Wilkinson KA, Lesosky M, Coussens AK, Deffur A, Pepper DJ et al (2014) Neutrophil-associated central nervous system inflammation in tuberculous meningitis immune reconstitution inflammatory syndrome. Clin Infect Dis 59:1638–1647
111. Gueders MM, Foidart JM, Noel A, Cataldo DD (2006) Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: potential implications in asthma and other lung diseases. Eur J Pharmacol 533:133–144
112. Park KJ, Hwang SC, Sheen SS, Oh YJ, Han JH, Lee KB (2005) Expression of matrix metalloproteinase-9 in pleural effusions of tuberculosis and lung cancer. Respir Int Rev Thoracic Dis 72:166–175
113. Elkington P, Shiomi T, Breen R, Nuttall RK, Ugarte-Gil CA, Walker NF et al (2011) MMP-1 drives immunopathology in human tuberculosis and transgenic mice. J Clin Invest 121:1827–1833
114. Tadokera R, Meintjes GA, Wilkinson KA, Skolimowska KH, Walker N, Friedland JS et al (2014) Matrix metalloproteinases and tissue damage in HIV-tuberculosis immune reconstitution inflammatory syndrome. Eur J Immunol 44:127–136
115. Martineau AR, Nhamoyebonde S, Oni T, Rangaka MX, Marais S, Bangani N et al (2011) Reciprocal seasonal variation in vitamin D status and tuberculosis notifications in Cape Town, South Africa. Proc Natl Acad Sci U S A 108:19013–19017
116. Coussens A, Timms PM, Boucher BJ, Venton TR, Ashcroft AT, Skolimowska KH et al (2009) 1alpha,25-dihydroxyvitamin D3 inhibits matrix metalloproteinases induced by Mycobacterium tuberculosis infection. Immunology 127:539–548
117. Coussens AK, Wilkinson RJ, Hanifa Y, Nikolayevskyy V, Elkington PT, Islam K et al (2012) Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. Proc Natl Acad Sci U S A 109:15449–15454
118. Price P, Haddow LJ, Affandi J, Agarwal U, Easterbrook PJ, Elliott J et al (2012) Short communication: plasma levels of vitamin D in HIV patients initiating antiretroviral therapy do not predict immune restoration disease associated with Mycobacterium tuberculosis. AIDS Res Hum Retrovir 28:1216–1219
119. Price P, Morahan G, Huang D, Stone E, Cheong KY, Castley A et al (2002) Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases. Aids 16:2043–2047
120. Affandi JS, Kumar M, Agarwal U, Singh S, Price P (2013) The search for a genetic factor associating with immune restoration disease in HIV patients co-infected with Mycobacterium tuberculosis. Dis Markers 34:445–449
121. Simonney N, Dewulf G, Herrmann JL, Gutierrez MC, Vicaut E, Boutron C et al (2008) Anti-PGL-Tb1 responses as an indicator of the immune restoration syndrome in HIV-TB patients. Tuberculosis 88:453–461
122. Sumatoh HR, Oliver BG, Kumar M, Elliott JH, Vonthanak S, Vun MC et al (2011) Mycobacterial antibody levels and immune restoration disease in HIV patients treated in South East Asia. Biomark Med 5:847–853
123. Phuah JY, Mattila JT, Lin PL, Flynn JL (2012) Activated B cells in the granulomas of nonhuman primates infected with Mycobacterium tuberculosis. Am J Pathol 181:508–514
124. Maertzdorf J, Repsilber D, Parida SK, Stanley K, Roberts T, Black G et al (2011) Human gene expression profiles of susceptibility and resistance in tuberculosis. Genes Immun 12:15–22
125. Lai RP, Meintjes G, Wilkinson KA, Graham CM, Marais S, van der Plas H et al (2015) HIV-tuberculosis-associated immune reconstitution inflammatory syndrome is characterized by toll-like-receptor and inflammasome signaling. Nat Commun 6:8451
126. Van den Bergh R, Vanham G, Raes G, De Baetselier P, Colebunders R (2006) Mycobacterium-associated immune reconstitution disease: macrophages running wild? Lancet Infect Dis 6:2–3, author reply 4–5
127. Cicala C, Arthos J, Martinelli E, Censoplano N, Cruz CC, Chung E et al (2006) R5 and X4 HIV envelopes induce distinct gene expression profiles in primary peripheral blood mononuclear cells. Proc Natl Acad Sci U S A 103:3746–3751
128. Dudhane A, Conti B, Orlikowsky T, Wang ZQ, Mangla N, Gupta A et al (1996) Monocytes in HIV type 1-infected individuals lose expression of costimulatory B7 molecules and acquire cytotoxic activity. AIDS Res Hum Retrovir 12:885–892
129. Pulliam L, Sun B, Rempel H (2004) Invasive chronic inflammatory monocyte phenotype in subjects with high HIV-1 viral load. J Neuroimmunol 157:93–98
130. Lawn SD, Wainwright H, Orrell C (2009) Fatal unmasking tuberculosis immune reconstitution disease with bronchiolitis obliterans organizing pneumonia: the role of macrophages. Aids 23:143–145
131. Tran HT, Van den Bergh R, Loembe MM, Worodria W, Mayanja-Kizza H, Colebunders R et al (2013) Modulation of the complement system in monocytes contributes to tuberculosis-associated immune reconstitution inflammatory syndrome. Aids 27:1725–1734
132. Tran HT, Van den Bergh R, Vu TN, Laukens K, Worodria W, Loembe MM et al (2014) The role of monocytes in the development of tuberculosis-associated immune reconstitution inflammatory syndrome. Immunobiology 219:37–44
133. Dunkelberger JR, Song WC (2010) Complement and its role in innate and adaptive immune responses. Cell Res 20:34–50
134. Andrade BB, Singh A, Narendran G, Schechter ME, Nayak K, Subramanian S et al (2014) Mycobacterial antigen driven activation of CD14++CD16- monocytes is a predictor of tuberculosis-associated immune reconstitution inflammatory syndrome. PLoS Pathog 10, e1004433
135. Roy S, Barnes PF, Garg A, Wu S, Cosman D, Vankayalapati R (2008) NK cells lyse T regulatory cells that expand in response to an intracellular pathogen. J Immunol 180:1729–1736
136. Vankayalapati R, Wizel B, Weis SE, Safi H, Lakey DL, Mandelboim O et al (2002) The NKp46 receptor contributes to NK cell lysis of mononuclear phagocytes infected with an intracellular bacterium. J Immunol 168:3451–3457
137. Vankayalapati R, Klucar P, Wizel B, Weis SE, Samten B, Safi H et al (2004) NK cells regulate CD8+ T cell effector function in response to an intracellular pathogen. J Immunol 172:130–137
138. Conradie F, Foulkes AS, Ive P, Yin X, Roussos K, Glencross DK et al (2011) Natural killer cell activation distinguishes Mycobacterium tuberculosis-mediated immune reconstitution syndrome from chronic HIV and HIV/MTB coinfection. J Acquir Immune Defic Syndr 58:309–318
139. Pean P, Nerrienet E, Madec Y, Borand L, Laureillard D, Fernandez M et al (2012) Natural killer cell degranulation capacity predicts early onset of the immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients with tuberculosis. Blood 119:3315–3320
140. Chackerian A, Alt J, Perera V, Behar SM (2002) Activation of NKT cells protects mice from tuberculosis. Infect Immun 70:6302–6309
141. Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, Oni T et al (2010) An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466:973–977
142. Dorhoi A, Yeremeev V, Nouailles G, Weiner J 3rd, Jorg S, Heinemann E et al (2014) Type I IFN signaling triggers immunopathology in tuberculosis-susceptible mice by modulating lung phagocyte dynamics. Eur J Immunol 44:2380–2393
143. Abel B, Thieblemont N, Quesniaux VJ, Brown N, Mpagi J, Miyake K et al (2002) Toll-like receptor 4 expression is required to control chronic Mycobacterium tuberculosis infection in mice. J Immunol 169:3155–3162
144. Reiling N, Holscher C, Fehrenbach A, Kroger S, Kirschning CJ, Goyert S et al (2002) Cutting edge: Toll-like receptor (TLR)2- and TLR4-mediated pathogen recognition in resistance to airborne infection with Mycobacterium tuberculosis. J Immunol 169:3480–3484
145. Tan DB, Lim A, Yong YK, Ponnampalavanar S, Omar S, Kamarulzaman A et al (2011) TLR2-induced cytokine responses may characterize HIV-infected patients experiencing mycobacterial immune restoration disease. Aids 25:1455–1460
146. Barber DL, Mayer-Barber KD, Antonelli LR, Wilson MS, White S, Caspar P et al (2010) Th1-driven immune reconstitution disease in Mycobacterium avium-infected mice. Blood 116:3485–3493
147. Hatziioannou T, Evans DT (2012) Animal models for HIV/AIDS research. Nat Rev Microbiol 10:852–867